Qiagen ( (QGEN) ) has issued an update.
Qiagen N.V. announced a manager’s transaction involving Elizabeth Tallett, a member of its supervisory body. The transaction included the release of restricted stock units granted in previous years and the receipt of common shares upon net share settlement, with a new grant of restricted stock units. This announcement reflects Qiagen’s ongoing management of executive compensation and stock option programs, potentially impacting shareholder value and executive incentives.
More about Qiagen
Qiagen N.V. operates in the biotechnology industry, specializing in providing sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research. The company is known for its focus on enabling customers to gain valuable insights from the building blocks of life, such as DNA, RNA, and proteins.
YTD Price Performance: -13.75%
Average Trading Volume: 1,094,687
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.36B
For detailed information about QGEN stock, go to TipRanks’ Stock Analysis page.